의료진프로필

Impact of Lactate Dehydrogenase and Hemoglobin Levels on Clinical Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From the National Korean PNH Registry

Jang, JH; Kim, JS; Lim, CTK; Kleinman, NJ; Myren, KJ; Wang, A; Patel, Y; Lee, JW

Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea

Kim, JS; Jang, JH; Jo, DY; Ahn, SY; Yoon, SS; Lee, JH; Kim, SH; Choi, CW; Shin, HJ; Kim, MK; Lee, JH; Mun, YC; Kong, JH; Hyun, B; Nam, H; Kim, E; Kwak, MJ; Won, YK; Lee, JW

Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE

Wong, RSM; Yavasoglu, I; Yassin, MA; Tarkun, P; Yoon, SS; Wei, X; Elghandour, A; Angchaisuksiri, P; Ozcan, M; Yang, RC; Mattar, M; Rahman, M; Ingles, S; Goldbrunner, M; Frueh, JA; Jang, JH

Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia

Ahn, SY; Kim, T; Kim, M; Song, GY; Jung, SH; Yang, DH; Lee, JJ; Kim, MY; Jung, CW; Jang, JH; Kim, HJ; Moon, JH; Sohn, SK; Won, JH; Kim, SH; Kim, HJ; Ahn, JS; Kim, DDH

Biosimilars in rare diseases : a focus on paroxysmal nocturnal hemoglobinuria

Kulasekararaj, A; Brodsky, R; Kulagin, A; Jang, JH

Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial

Wei, AH; Dohner, H; Sayar, H; Ravandi, F; Montesinos, P; Dombret, H; Selleslag, D; Porkka, K; Jang, JH; Skikne, B; Beach, CL; Prebet, T; Zhang, GR; Risueno, A; Ugidos, M; See, WL; Menezes, D; Roboz, GJ

Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms

Kim, HY; Han, Y; Jang, JH; Jung, CW; Kim, SH; Kim, HJ

Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study

Jonas, BA; DiNardo, C; Fracchiolla, N; Pristupa, A; Ishizawa, K; Jin, J; Konopleva, M; Ofran, Y; Montesinos, P; Kovacsovics, T; Jang, JH; Kantarjian, H; Duan, YH; Potluri, J; Werner, M; Pratz, KW

Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia

Song, GY; Kim, T; Ahn, SY; Jung, SH; Kim, M; Yang, DH; Lee, JJ; Choi, SH; Kim, MY; Jung, CW; Jang, JH; Kim, HJ; Moon, JH; Sohn, SK; Won, JH; Park, SK; Kim, SH; Zhang, ZL; Ahn, JS; Kim, HJ; Kim, DDH

Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study

Jang, JH; Wong, L; Ko, BS; Yoon, SS; Li, K; Baltcheva, I; Nidamarthy, PK; Chawla, R; Junge, G; Yap, ES

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia

Jonas, BA; Wei, AH; Recher, C; DiNardo, CD; Jang, JH; Pratz, K; Panayiotidis, P; Montesinos, P; Yeh, SP; Ivanov, V; Fiedler, W; Yamauchi, T; Duan, YH; Mendes, W; Potluri, J; Tews, B; Ofran, Y

Measurable Residual Disease Response and Prognosis in Treatment-Naive Acute Myeloid Leukemia With Venetoclax and Azacitidine

Pratz, KW; Jonas, BA; Pullarkat, V; Recher, C; Schuh, AC; Thirman, MJ; Garcia, JS; DiNardo, CD; Vorobyev, V; Fracchiolla, NS; Yeh, SP; Jang, JH; Ozcan, M; Yamamoto, K; Illes, A; Zhou, Y; Dail, M; Chyla, B; Potluri, J; Dohner, H

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial

Roboz, GJ; Dohner, H; Pocock, C; Dombret, H; Ravandi, F; Jang, JH; Selleslag, D; Mayer, JR; Martens, UM; Liesveld, J; Bernal, T; Wang, MC; Yu, PW; Shi, L; Guo, S; La Torre, I; Skikne, B; Dong, Q; Braverman, J; Nehme, SA; Beach, CL; Wei, AH

Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)

Cho, EH; Kim, JY; Im, SA; Jung, KH; Sohn, J; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Jang, JH; Ahn, JH; Park, MS; Lee, SY; Park, YH

Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric CD34(+) cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation

Kim, SM; Kim, HY; Kim, SJ; Jang, JH; Kim, K; Kim, WS; Jung, CW; Cho, D; Kang, ES

Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Kobayashi¹, Y; Oh, I; Miyamoto, T; Lee, WS; Iida, H; Minami, H; Maeda, Y; Jang, JH; Yoon, SS; Yeh, SP; Tran, Q; Morris, J; Franklin, J; Kiyoi, H

LSAMP Rearrangement in Acute Myeloid Leukemia With a Jumping Translocation Involving 3q13.31

Yoon¹, J; Cho, EH; Yun, JW; Kim, HY; Jang, JH; Kim, HJ; Kim, SH

Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome

Jung¹, HA; Jung, CW; Jang, JH

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study

Steensma¹, DP; Fenaux, P; Van Eygen, K; Raza, A; Santini, V; Germing, U; Font, P; Diez-Campelo, M; Thepot, S; Vellenga, E; Patnaik, MM; Jang, JH; Varsos, H; Bussolari, J; Rose, E; Sherman, L; Sun, LB; Wan, Y; Dougherty, S; Huang, F; Feller, F; Rizo, A; Platzbecker, U

Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study

Jang¹, JH; Tomiyama, Y; Miyazaki, K; Nagafuji, K; Usuki, K; Uoshima, N; Fujisaki, T; Kosugi, H; Matsumura, I; Sasaki, K; Kizaki, M; Sawa, M; Hidaka, M; Kobayashi, N; Ichikawa, S; Yonemura, Y; Enokitani, K; Matsuda, A; Ozawa, K; Mitani, K; Lee, JW; Nakao, S

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

Wei¹, AH; Dohner, H; Pocock, C; Montesinos, P; Afanasyev, B; Dombret, H; Ravandi, F; Sayar, H; Jang, JH; Porkka, K; Selleslag, D; Sandhu, I; Turgut, M; Giai, V; Ofran, Y; Cakar, MK; de Sousa, AB; Rybka, J; Frairia, C; Borin, L; Beltrami, G; Cermak, J; Ossenkoppele, GJ; La Torre, I; Skikne, B; Kumar, K; Dong, Q; Beach, CL; Roboz, GJ

Association between body image dissatisfaction and poor quality of life and depression among patients with hematopoietic stem cell transplantation

Kang¹, D; Kim, IR; Choi, HJ; Jung, CW; Yoon, SS; Kim, JS; Lee, CH; Jang, JH; Cho, J

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

DiNardo¹, CD; Jonas, BA; Pullarkat, V; Thirman, MJ; Garcia, JS; Wei, AH; Konopleva, M; Dohner, H; Letai, A; Fenaux, P; Koller, E; Havelange, V; Leber, B; Esteve, J; Wang, J; Pejsa, V; Hajek, R; Porkka, K; Illes, A; Lavie, D; Lemoli, RM; Yamamoto, K; Yoon, SS; Jang, JH; Yeh, SP; Turgut, M; Hong, WJ; Zhou, Y; Potluri, J; Pratz, KW

Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies

de Latour¹, RP; Brodsky, RA; Ortiz, S; Risitano, AM; Jang, JH; Hillmen, P; Kulagin, AD; Kulasekararaj, AG; Rottinghaus, ST; Aguzzi, R; Gao, X; Wells, RA; Szer, J

Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation

Maertens¹, J; Logan, AC; Jang, J; Long, G; Tang, JL; Hwang, WYK; Koh, LP; Chemaly, R; Gerbitz, A; Winkler, J; Yeh, SP; Hiemenz, J; Christoph, S; Lee, DG; Wang, PN; Holler, E; Mielke, S; Akard, L; Yeo, A; Ramachandra, S; Smith, K; Pertel, P; Segal, F

Relationship of Circulating Cytomegalovirus Levels Obtained Through Antigenemia Testing and Quantitative PCR Differs Between Children and Adults

Choi¹, S; Kim, YJ; Yoo, KH; Sung, KW; Koo, HH; Kim, SJ; Jang, JH; Kim, K; Jung, CW; Huh, HJ; Kang, ES

Anti-leukemic effects of simvastatin on NRAS(G12D) mutant acute myeloid leukemia cells

Jang¹, J; Lee, J; Jang, JH; Jung, CW; Park, S

Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial

Lee¹, JW; Lee, SE; Jung, CW; Park, S; Keta, H; Park, SK; Kim, JA; Oh, IH; Jang, JH

Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria

Sakurai¹, M; Jang, JH; Chou, WC; Kim, JS; Wilson, A; Nishimura, J; Chiou, TJ; Kanakura, Y; Lee, JW; Okamoto, S

Prospective randomized trial comparing two doses of rabbit anti-thymocyte globulin in patients with severe aplastic anaemia

Narita¹, A; Zhu, XF; Muramatsu, H; Chen, XJ; Guo, Y; Yang, WY; Zhang, JL; Liu, F; Jang, JH; Kook, H; Kim, H; Usuki, K; Yamazaki, H; Takahashi, Y; Nakao, S; Lee, JW; Kojima, S

Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System

Jung¹, KS; Kim, YJ; Kim, YK; Park, SK; Kim, HG; Kim, SJ; Park, J; Choi, CW; Do, YR; Kim, I; Park, S; Mun, YC; Jeong, SH; Kim, MK; Yi, HG; Chang, MH; Kim, SY; Lee, JH; Jang, JH

Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysis

Kim¹, JS; Cheong, JW; Mun, YC; Jang, JH; Jo, DY; Lee, JW

Different prognostic effects of core-binding factor positive AML with Korean AML registry data

Shin¹, HJ; Min, WS; Min, YH; Cheong, JW; Lee, JH; Kim, IH; Hong, DS; Ahn, JS; Kim, HJ; Lee, WS; Jung, CW; Jang, JH; Park, Y; Kim, HJ

Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study

Frey¹, N; Jang, JH; Szer, J; Illes, A; Kim, HJ; Ram, R; Chong, BH; Rowe, JM; Borisenkova, E; Liesveld, J; Winer, ES; Cherfi, A; Aslanis, V; Ghaznawi, F; Strickland, S

Utility of allogeneic hematopoietic stem cell transplantation using international donors in a homogenous ethnic population: question in the era of various alternative donors

Kim¹, SA; Lee, J; Moon, JH; Lee, H; Jang, J; Cheong, JW; Youk, J; Choi, Y; Kang, M; Shin, M; Koh, Y; Shin, S

Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry

Lee¹, JW; de Latour, RP; Brodsky, RA; Jang, JH; Hill, A; Roth, A; Schrezenmeier, H; Wilson, A; Marantz, JL; Maciejewski, JP

Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia

Kim¹, HY; Lee, KO; Park, S; Jang, JH; Jung, CW; Kim, SH; Kim, HJ

Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study

Yoo¹, KH; Kang, D; Kim, IR; Choi, EK; Kim, JS; Yoon, SS; Lee, CH; Park, S; Kim, SJ; Kim, K; Kim, WS; Jung, CW; Choi, HJ; Jang, JH; Cho, J

Which donor is better when a matched donor is not available domestically? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population

Park¹, H; Lee, YJ; Shin, SJ; Lee, J; Park, S; Kim, I; Moon, JH; Lee, H; Jang, JH; Yoon, SS; Koh, Y

Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype

Ahn¹, JS; Kim, HJ; Kim, YK; Lee, SS; Ahn, SY; Jung, SH; Yang, DH; Lee, JJ; Park, HJ; Lee, JY; Choi, SH; Jung, CW; Jang, JH; Kim, HJ; Moon, JH; Sohn, SK; Lee, YJ; Won, JH; Kim, SH; Zhang, ZL; Kim, T; Kim, DDH

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Seymour¹, JF; Dohner, H; Butrym, A; Wierzbowska, A; Selleslag, D; Jang, JH; Kumar, R; Cavenagh, J; Schuh, AC; Candoni, A; Recher, C; Sandhu, I; del Castillo, TB; Al-Ali, HK; Falantes, J; Stone, RM; Minden, MD; Weaver, J; Songer, S; Beach, CL; Dombret, H

Atypical presentations of MERS-CoV infection in immunocompromised hosts

Kim¹, SH; Ko, JH; Park, GE; Cho, SY; Ha, YE; Kang, JM; Kim, YJ; Huh, HJ; Ki, CS; Jeong, BH; Park, J; Jang, JH; Kim, WS; Kang, CI; Chung, DR; Song, JH; Peck, KR

Epidemiology and Risk Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients in Korea: Results of "RISK" Study

Choi¹, JK; Cho, SY; Yoon, SS; Moon, JH; Kim, SH; Lee, JH; Kim, JS; Cheong, JW; Jang, JH; Seo, BJ; Kim, YJ; Lee, HJ; Lee, J; Lee, JW; Lee, DG

Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma

Kim HS1¹, Lee JY2, Lim SH2, Cho J3, Kim SJ2, Jang JH2, Kim WS2, Jung CW2, Kim K4.

5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia

Ahn JS1¹,2, Kim HJ1,2, Kim YK1,2, Lee SS1, Ahn SY1, Jung SH1, Yang DH1, Lee JJ1, Park HJ2, Choi SH2, Jung CW3, Jang JH3, Kim HJ4, Moon JH5, Sohn SK5, Won JH6, Kim SH7, Michael S8, Minden MD9, Kim DD9.

Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients

Park S1¹, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Chung DR2, Kang CI2, Peck KR2, Jung CW3.

Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation

Park S1¹, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Jung CW1.

High frequency of JAK2 exon 12 mutations in Korean patients with polycythaemia vera: novel mutations and clinical significance

Park CH1¹, Lee KO2, Jang JH3, Jung CW3, Kim JW1, Kim SH1, Kim HJ1.

Cytogenetic profiles of 2806 patients with acute myeloid leukemia-a retrospective multicenter nationwide study

Byun JM1¹, Kim YJ2, Yoon HJ3, Kim SY3, Kim HJ4, Yoon J4, Min YH5, Cheong JW5, Park J6, Lee JH6, Hong DS7, Park SK7, Kim HJ8, Ahn JS8, Shin HJ9, Chung JS9, Lee WS10, Lee SM10, Park Y11, Kim BS11, Lee JH12, Lee KH12, Jung CW13, Jang JH13, Min WS14, Park TS15; AML/MDS working party of Korean Society of Hematology.

Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC QLQ-HDC29)

Kim KI1¹, Kim JH2, Ji EH3, Jang JH4, Kim JS5, Kwon JH6, Kim I7,8,9, Park S7,8,9, Velikova G10, Yoon SS11,12,13, Oh JM14,15.

Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML

Ahn JS1¹, Kim HJ2, Kim YK1, Jung SH1, Yang DH1, Lee JJ1, Kim NY3, Choi SH3, Jung CW4, Jang JH4, Kim HJ5, Moon JH6, Sohn SK6, Won JH7, Kim SH8, Kim DD9.

Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry

Jang JH1¹, Kim JS2, Yoon SS3, Lee JH4, Kim YK5, Jo DY6, Chung J7, Sohn SK8, Lee JW9.

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

Roboz GJ1¹, Montesinos P2, Selleslag D3, Wei A4, Jang JH5, Falantes J6, Voso MT7, Sayar H8, Porkka K9, Marlton P10, Almeida A11, Mohan S12, Ravandi F13, Garcia-Manero G13, Skikne B14, Kantarjian H13.

Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis

Lim SH1¹, Park S1, Jang JH1, Kim K1, Kim HJ2, Kim SH2, Kang CI3, Chung DR3, Peck KR3, Lee J4, Cha HS4, Koh EM4, Ko YH5, Kim WS1, Jung CW1, Kim SJ6,7.

Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: results from South Korean National PNH Registry

Kim JS1¹, Jang JH2, Yoon SS3, Lee JH4, Kim YK5, Jo DY6, Chung JS7, Sohn SK8, Lee JW9.

DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Ahn JS1¹, Kim HJ2, Kim YK1, Lee SS1, Jung SH1, Yang DH1, Lee JJ1, Kim NY3, Choi SH3, Jung CW4, Jang JH4, Kim HJ5, Moon JH6, Sohn SK6, Won JH7, Kim SH8, Kim DD9.

Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study

Jeong SH1¹, Kim DY2, Jang JH3, Mun YC4, Choi CW5, Kim SH6, Kim JS7, Park JS8.

Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia

Park S1¹, Yoon SS2, Lee JH3, Park JS4, Jang JH5, Lee JW6.

Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant

Ahn JS1¹, Kim JY1, Kim HJ2, Kim YK1, Lee SS1, Jung SH1, Yang DH1, Lee JJ1, Kim NY3, Choi SH3, Minden MD4, Jung CW5, Jang JH5, Kim HJ6, Moon JH7, Sohn SK7, Won JH8, Kim SH9, Kim DD4.

A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome

Jeong SH1¹, Kim YJ2, Lee JH3, Kim YK4, Kim SJ5, Park SK6, Do YR7, Kim I8, Mun YC9, Kim HG10, Lee WS11, Yi HG12, Joo YD13, Choi CW14, Kim SR15, Na SM15, Jang JH16.

Iron deficient erythropoiesis might play key role in development of anemia in cancer patients

Park S1¹, Jung CW1, Kim K1, Kim SJ1, Kim WS1, Jang JH1.

Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy

Lee JY1¹, Lim SH1, Lee MY1, Kim H1, Sinn DH1, Gwak GY1, Choi MS1, Lee JH1, Jung CW1, Jang JH1, Kim WS1, Kim SJ1, Kim K1.

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes

Jang JH1¹, Harada H2,3, Shibayama H4, Shimazaki R5, Kim HJ6, Sawada K7, Mitani K8.

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial

Platzbecker U1¹, Wong RS2, Verma A3, Abboud C4, Araujo S5, Chiou TJ6, Feigert J7, Yeh SP8, Gotze K9, Gorin NC10, Greenberg P11, Kambhampati S12, Kim YJ13, Lee JH14, Lyons R15, Ruggeri M16, Santini V17, Cheng G18, Jang JH19, Chen CY20, Johnson B21, Bennett J22, Mannino F23, Kamel YM24, Stone N23, Dougherty S23, Chan G23, Giagounidis A25.

Single monosomy as a relatively better survival factor in acute myeloid leukemia patients with monosomal karyotype

Jang JE1¹, Min YH1, Yoon J2, Kim I3, Lee JH4, Jung CW5, Shin HJ6, Lee WS7, Lee JH8, Hong DS9, Kim HJ10, Kim HJ2, Park S3, Lee KH4, Jang JH5, Chung JS6, Lee SM7, Park J8, Park SK9, Ahn JS10, Min WS2, Cheong JW1; Korean Society of Hematology AML/MDS Working Party.

Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma

Park S1¹, Jung CW1, Jang JH1, Kim SJ1, Kim WS1, Kim K1.

Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype

Ahn JS1¹, Kim HJ2, Kim YK1, Jung SH1, Yang DH1, Lee JJ1, Lee IK3, Kim NY3, Minden MD4, Jung CW5, Jang JH5, Kim HJ6, Moon JH7, Sohn SK7, Won JH8, Kim SH9, Kim N10, Yoshida K11, Ogawa S11, Kim DD4.

KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study

Park S1¹, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Kang ES2, Jung CW3.

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Dombret H1¹, Seymour JF2, Butrym A3, Wierzbowska A4, Selleslag D5, Jang JH6, Kumar R7, Cavenagh J8, Schuh AC9, Candoni A10, Recher C11, Sandhu I12, Bernal del Castillo T13, Al-Ali HK14, Martinelli G15, Falantes J16, Noppeney R17, Stone RM18, Minden MD9, McIntyre H19, Songer S19, Lucy LM19, Beach CL19, Dohner H20.

Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients

Jung HA1¹,2, Maeng CH3, Kim M1, Kim S1, Jung CW1, Jang JH1.

Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome

Ahn JS1¹, Kim YK, Min YH, Cheong JW, Jang JH, Jung CW, Kim IH, Yoon HJ, Lee HG, Sohn SK, Moon JH, Kim H, Kim YJ, Won JH, Chung JS, Mun YC, Lee JH, Kim HJ.

A case of CD5-positive mature B-cell neoplasm with t(10;14)(q24;q11.2) and trisomy 12

Shin SY1¹, Lee ST, Kim HJ, Jang JH, Jung CW, Kim SH.

Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome

Hong JY1¹, Seo JY2, Kim SH3, Jung HA4, Park S4, Kim K4, Jung CW4, Kim JS5, Park JS6, Kim HJ7, Jang JH8.

Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia

Stone RM1¹, Mazzola E2, Neuberg D2, Allen SL2, Pigneux A2, Stuart RK2, Wetzler M2, Rizzieri D2, Erba HP2, Damon L2, Jang JH2, Tallman MS2, Warzocha K2, Masszi T2, Sekeres MA2, Egyed M2, Horst HA2, Selleslag D2, Solomon SR2, Venugopal P2, Lundberg AS2, Powell B2.

Two Cases of Acute Lymphoblastic Leukemia with an ela3 BCR-ABL1 Fusion Transcript

Shin SY1¹, Cho JH1, Kim HJ1, Jang JH2, Lee ST1, Kim SH1.

A new HLA-A*30 allele, A*30:81, identified by sequence-based typing

Yoon YA1¹, Kim JS, Yoon CE, Jang JH, Kang ES.

Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience

Lee KH1¹, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW, Kim DW, Kang ES.

Spinal cord compression in multiple myeloma: a single center experience

Jung HA1¹, Cho SH, Kim SJ, Jang JH, Kim WS, Jung CW, Kim K.

Renal Insufficiency in Newly-diagnosed Multiple Myeloma: Analysis According to International Myeloma Working Group Consensus Statement

Park S1¹, Han B2, Kim K3, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.

Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma

Kim SM1¹, Kim MJ1, Jung HA1, Kim K1, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.

Hereditary gene mutations in Korean patients with isolated erythrocytosis

Jang JH1¹, Seo JY, Jang J, Jung CW, Lee KO, Kim SH, Kim HJ.

Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients

Park S1¹, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Jung CW, Jang JH, Kim SJ, Kim WS, Choi JY, Kim K.

Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes

Kim Y1¹, Kim IH, Kim HJ, Park S, Lee KH, Kim SJ, Lee JH, Kim DY, Yoon SS, Kim YK, Jang JH, Park SY, Ahn JS, Cheong CW, Lee JH, Cheong JW; Korean Society of Hematology Acute myeloid Leukemia/Myelodysplastic Syndrome Working Party.

Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts

Seo JY1¹,?Lee KO,?Kim SH,?Kim K,?Jung CW,?Jang JH,?Kim HJ.

Prognostic Factor Analysis in Core-Binding Factor-positive Acute Myeloid Leukemia

Jung HA1¹, Maeng CH, Park S, Kim SJ, Kim K, Jang JH, Jung CW.

Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies: A Multicenter, Prospective, Open-Label, Observational Study in Korea

Kim SJ1¹, Cheong JW1, Min YH1, Choi YJ2, Lee DG3, Lee JH4, Yang DH5, Lee SM6, Kim SH7, Kim YS8, Kwak JY9, Park J10, Kim JY11, Kim HG12, Kim BS13, Ryoo HM14, Jang JH15, Kim MK16, Kang HJ17, Cho IS18, Mun YC19, Jo DY20, Kim HY21, Park BB22, Kim JS1.

DCEP for relapsed or refractory multiple myeloma after therapy with novel agents

Park S1¹, Lee SJ, Jung CW, Jang JH, Kim SJ, Kim WS, Kim K.

Korean Guideline for Iron Chelation Therapy in Transfusion-Induced Iron Overload

Jang JH1¹,?Lee JH,?Yoon SS,?Jo DY,?Kim HJ,?Chung J,?Lee JW;?Korean?Society of Hematology Aplastic Anemia Working Party.

Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry

Lee JW1¹,?Jang JH,?Kim JS,?Yoon SS,?Lee JH,?Kim YK,?Jo DY,?Chung J,?Sohn SK.

Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity

Ahn HK1¹, Jang JH, Kim K, Kim HJ, Kim SH, Jung CW, Kim DH.

A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome

Lee JH1¹,?Jang JH,?Park J,?Park S,?Joo YD,?Kim YK,?Kim HG,?Choi CW,?Kim SH,?Park SK,?Park E,?Min YH.

External Validation of Newly Proposed Cytogenetic Risk Classification in Patients Who Have Myelodysplastic Syndrome: A Retrospective Analysis at a Single Institution

Yun J1¹,?Kim DH,?Kong JH,?Kim HJ,?Kim SH,?Kim K,?Jang JH,?Jung CW.

Feasibility of Second Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning with Fludarabine and Melphalan after a Failed Autologous Hematopoietic Stem Cell Transplantation

Hong JY1¹,?Choi MK,?Kim DH,?Kim SJ,?Kim K,?Kim WS,?Chung CW,?Kim HO,?Min YH,?Jang JH.

Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience

Iastrebner M1¹,?Jang JH,?Nucifora E,?Kim K,?Sackmann F,?Kim DH,?Orlando S,?Jung CW,?Basquiera A,?Klein G,?Santini F,?Bernard HI,?Korin J,?Taborda G.

Efficacy and Safety of Micafungin as an Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases

Park JS1¹,?Kim DH,?Choi CW,?Jeong SH,?Choi JH,?Kim K,?Kim SJ,?Jung CW,?Yang DH,?Jang JH.

A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation

Kim ST1¹, Lee MH, Kim SY, Kim SJ, Kim DH, Jang JH, Kim K, Kim WS, Jung CW.

Gastric Recurrence of Extramedullary Granulocytic Sarcoma After Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Choi ER1¹, Ko YH, Kim SJ, Jang JH, Kim K, Kang WK, Jung CW, Kim DH.

BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients

Moon JH1¹, Sohn SK, Lee MH, Jang JH, Kim K, Jung CW, Kim DH.

Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS

Park MJ1¹,?Kim HJ,?Kim SH,?Kim DH,?Kim SJ,?Jang JH,?Kim K,?Kim WS,?Jung CW.